ReviewFrontiers in immunology2014
Eosinophilic granulomatosis with polyangiitis: an overview.
Review in Frontiers in immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 208 citations in OpenAlex.
- Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.The Journal of allergy and clinical immunology · 2019Trial
- Risk factors for thrombosis in eosinophilia: A case-control study.Scientific reports · 2026Article
- From Nerves to Vessels: Unmasking Churg-Strauss Behind Polyneuropathy.Clinical case reports · 2026Article
- Anesthetic Management of Eosinophilic Granulomatosis with Polyangiitis: A Narrative Review with an Illustrative Case in Cardiac Surgery.Journal of personalized medicine · 2026Review
- Steroid-Free Remission of Eosinophilic Granulomatosis With Polyangiitis Achieved With Low-Dose Mepolizumab: A Case Report.Clinical case reports · 2026Article
- EGPAware: a European Delphi consensus study on red flags for suspicion of eosinophilic granulomatosis with polyangiitis.EULAR rheumatology open · 2026Article
- Mapping a path forward: addressing disease burden, pathways and solutions in ANCA-associated vasculitis.Rheumatology (Oxford, England) · 2026Review
- A Rare Case of Eosinophilic Granulomatosis with Polyangiitis Following Development of Central Diabetes Insipidus: A Case Report and Literature Review.Internal medicine (Tokyo, Japan) · 2026Review
- Targeting the complement system in ANCA-associated vasculitis management.Rheumatology (Oxford, England) · 2026Review
- Article
- Molecular Pathogenesis and Targeted Therapies in Eosinophilic Granulomatosis with Polyangiitis: An Updated Review.International journal of molecular sciences · 2025Review
- A presentation of recurrent cerebral ischemic stroke in eosinophilic granulomatosis with polyangiitis: a case report.Journal of medical case reports · 2025Article
- Article
- Kimura disease and eosinophilic granulomatosis with polyangiitis: Clinical and imaging overlap of 2 immune-mediated conditions.Radiology case reports · 2025Article
- Hypereosinophilic Disorders.The journal of allergy and clinical immunology. In practice · 2025Article
- The Role of Bronchoscopy in the Diagnosis of Interstitial Lung Disease: A State-of-the-Art Review.Journal of clinical medicine · 2025Review
- Eosinophilic Granulomatosis With Polyangiitis Presenting With Visual Problems and Subendocardial Fibrosis, A Case Report.Clinical case reports · 2025Article
- Similarities and differences of clinical manifestations and prognosis between eosinophilic gastroenteritis and eosinophilic granulomatosis with polyangiitis complicating gastrointestinal involvement.Clinical rheumatology · 2025Article
- Clinical and Pathophysiological Tangles Between Allergy and Autoimmunity: Deconstructing an Old Dichotomic Paradigm.Clinical reviews in allergy & immunology · 2025Review
- Clinical value at baseline and follow-up of myeloperoxidase-antibodies in ANCA-associated vasculitis.Frontiers in immunology · 2025Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eosinophilic granulomatosis with polyangiitis (EGPA) is a multisystemic disorder, belonging to the small vessel anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, defined as an eosinophil-rich and necrotizing granulomatous inflammation often involving the respiratory tract, and necrotizing vasculitis predominantly affecting small to medium-sized vessels, associated with asthma and eosinophilia. EGPA pathogenesis is not well known: HLA-DRB1*04 and *07, HLA-DRB4 and IL10.2 haplotype of the IL-10 promoter gene are the most studied genetic determinants. Among the acquired pathogenetic factors, the exposure to different allergens, infections, vaccinations, drugs, and silica exposure have been involved. Eosinophils are the most characteristic cells in EGPA and different studies have demonstrated their role as effector and immunoregulatory cells. EGPA is considered as a disease with a prevalent activation of the Th-2 cellular-mediated inflammatory response and also humoral immunity plays an important role. A link between B and T inflammatory responses may explain different disease features. EGPA typically develops into three sequential phases: the allergic phase, distinguished by the occurrence of asthma, allergic rhinitis, and sinusitis, the eosinophilic phase, in which the main pathological finding is the eosinophilic organ infiltrations (e.g., lungs, heart, and gastrointestinal system), and the vasculitic phase, characterized by purpura, peripheral neuropathy, and constitutional symptoms. ANCA (especially pANCA anti-myeloperoxidase) are present in 40-60% of the patients. An elevation of IgG4 is frequently found. Corticosteroids and cyclophosphamide are classically used for remission induction, while azathioprine and methotrexate are the therapeutic options for remission maintenance. B-cell depletion with rituximab has shown promising results for remission induction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.